BioXcel Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• BioXcel Therapeutics Inc BTAI.OQ reported a quarterly adjusted loss of $2.45​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-3.36. The mean expectation of five analysts for the quarter was for a loss of $1.86 per share. Wall Street expected results to range from $-2.74 to $-1.13 per share.

• Revenue fell 89.1% to $120.00 thousand from a year ago; analysts expected $250.00 thousand.

• BioXcel Therapeutics Inc's reported EPS for the quarter was a loss of $2.45​.

• The company reported a quarterly loss of $19.19 million.

• BioXcel Therapeutics Inc shares had risen by 253.6% this quarter and gained 7.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 9.8% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for BioXcel Therapeutics Inc is $6.00, about 6.7% below its last closing price of $6.40

This summary was machine generated from LSEG data August 12 at 01:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)